Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although ICIs have proven highly effective for adult cancers, initial phase I/II clinical trials using single-agent ICIs against unselected pediatric cancers have been overall disappointing. With the exception of pediatric classic Hodgkin lymphoma, responses to ICIs have been infrequent, likely stemming from an inherent difference in the immunogenicity of childhood cancers, which, on average, have far fewer neoantigens than adult cancers. Recently, however, hope has reemerged that certain subsets of children with cancer may benefit from ICI therapies. In preliminary studies, patients with both pediatric hypermutated and SMARCB1-deficient cancers have had impressive responses to ICI therapies, likely as a result of underlying biologies that enhance neoantigen expression and tumoral inflammation. Dedicated trials are ongoing to fully evaluate the efficacy of ICIs for patients with these subsets of pediatric cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Across four prior studies evaluating ICI monotherapy regimens in children with solid tumors and lymphoma, the collective ORR was 3.7% for the solid tumor population (nine responses in 244 patients) (17).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [17]
In the citing paper
“Unfortunately, to date, no objective responses have been reported with any ICI combination regimen in young children (age <10 years) with a solid tumor (8, 17).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [17]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 3
- Loeb DM, Cancer Immunol Immunother.
- Morgenstern DA, 2021, J Clin Orthod., 39, 15
- Chung HC, 2018, J Clin Oncol., 36, 15
Cited by
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 74
“The failure of ICI in unselected pediatric cancers has led to recommendations of avoiding ICI monotherapy trials in children without robust biological rationale (19, 20).”
BackgroundSelf-citationImmune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma
Padilla, O. A., Minns, H. E., Wei, H.-J., Fan, W., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Gallitto, M., Yeh, R., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.219 · Cited by 42
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Ciurej, A., Lewis, E. C., Gupte, A., & Al‐Antary, E. T. (2023) · Vaccines · doi:10.3390/vaccines11121843 · Cited by 24
“Due, in part, to the low incidence of pediatric melanoma and resulting low sample size in related clinical trials, the FDA used extrapolation with adult patient data to approve ipilimumab for unresectable or metastatic melanoma in pediatric patients older than 12 years in 2017 [45].”
BackgroundMethodInfluentialMünter, D., de Faria, F. W., Richter, M., Aranda-Pardos, I., Hotfilder, M., Walter, C., Paga, E., Inserte, C., Albert, T., Roy, R., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.031 · Cited by 23
Deyell, R. J., Shen, Y., Titmuss, E., Dixon, K., Williamson, L. M., Pleasance, E., Nelson, J., Abbasi, S., Krzywinski, M. I., Armstrong, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48363-5 · Cited by 24
“A participant with chordoma and outlier high immune signature T-cell scores, but low TMB, achieved PR to single agent ICI therapy (LOE5) and an additional patient with a TRK fusion achieved PR to TRK inhibitor therapy (LOE4B at the time of MTB).”
InfluentialTargeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 20
“31,48,49 Therefore, discovery of RMS specific antigens, in particular of immune markers, is of highest importance to boost immunotherapies.”
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Singh, S. V., Fang, J., Jin, H., de Velde, L.-A. V., Cortes, A., Chen, J., Natarajan, S., Poon, E., Wu, Q., Morton, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63979-x · Cited by 16
“Pediatric solid tumors including neuroblastoma are generally immune “ cold ” , making it challenging to develop effective immune checkpoint blockade (ICB)therapies,as evidenced by clinical trials 84 .”
Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges
Pathania, A. S. (2024) · Cancers · doi:10.3390/cancers16122201 · Cited by 18
“Despite immunotherapy becoming a viable treatment option for many pediatric cancer patients, it does not work for everyone [188].”
BackgroundThe Role of Chronic Inflammation in Pediatric Cancer
Mella, C., Tsarouhas, P., Brockwell, M., & Ball, H. C. (2025) · Cancers · doi:10.3390/cancers17010154 · Cited by 14
Noncanonical microprotein regulation of immunity
Nichols, C. M., Do-Thi, V. A., & Peltier, D. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.021 · Cited by 13
Aging and Cancer—Inextricably Linked Across the Lifespan
DeGregori, J. V., Seidl, K. J., & Montano, M. A. (2025) · Aging Cell · doi:10.1111/acel.14483 · Cited by 12
ImmunoTar—integrative prioritization of cell surface targets for cancer immunotherapy
Shraim, R., Mooney, B., Conkrite, K. L., Hamilton, A. K., Morin, G. B., Sorensen, P. H. B., Maris, J. M., Diskin, S. J., & Saçan, A. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf060 · Cited by 12
“…treatments such as immune checkpoint inhibitors (ICIs), which have shown remarkable effectiveness in tumors with a high mutational burden such as melanoma and lung cancers; however, ICIs remain ineffective in most low mutational burden cancers such as childhood malignancies (Long et al. 2022).”
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Jaing, T., Wang, Y.-L., & Chiu, C.-C. (2024) · Pharmaceuticals · doi:10.3390/ph17080991 · Cited by 12
“…proteins formed due to genetic mutations in cancer cells This phenomenon occurs as a result of their inherent capacity to elicit an immune response [3]. phenomenon occurs as a result of their inherent capacity to elicit an immune response Neoantigens, like viral antigens, are not found in the…”
BackgroundResultInfluentialImmunotherapies for Childhood Cancer
Park, J. A., & Cheung, N. V. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041574 · Cited by 10
Moreno, L., Teira, P., Croop, J. M., Gerber, N. U., André, N., Aerts, I., Gros, L., Wilde, B. D., Bautista, F. J., Turpin, B. K., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1183295 · Cited by 8
Butters, C. T., Thursky, K., Hanna, D. T., Cole, T. S., Davidson, A. J., Buttery, J. P., & Haeusler, G. M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171987 · Cited by 8
“As the use of ICIs in children expands, concurrent exposure to antibiotics must be considered and adjusted for in future pediatric clinical trials [102].”
BackgroundMishra, D. K., Morris, S. M., Popovski, D., Girard, E. J., Bondoc, A., Kumar, S. S., Andrade, A. F., Zhu, X., Yao, F., Brusniak, M., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf241 · Cited by 9
Zhao, S. J., Prior, D., Heske, C. M., & Vasquez, J. C. (2024) · Cancers · doi:10.3390/cancers16091648 · Cited by 8
“While immune checkpoint blockade (ICB) has shown activity in the adult population, clinical trials in pediatric patients have generally yielded disappointing results, with the exception of Hodgkin lymphoma [164].”
BackgroundResultEbrahimi, S., Habibzadeh, A., Khojasteh‐Kaffash, S., Valizadeh, P., Samieefar, N., & Rezaei, N. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104225 · Cited by 7
Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
Gikandi, A., Chi, S. N., Yeo, K. K., O'Neill, A. F., Shulman, D. S., DuBois, S. G., & Collins, N. B. (2024) · Cancer Medicine · doi:10.1002/cam4.7154 · Cited by 7
Parisi, R., Patel, R. R., Rood, G. J., Bowden, A., Turco, G. M., Korones, D. N., Andolina, J. R., Comito, M., Barth, M. J., & Weintraub, L. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30139 · Cited by 7
Cupit-Link, M., Khan, R. B., Pappo, A. S., & Helmig, S. E. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100117 · Cited by 7
Marjańska, A., Pawińska-Wąsikowska, K., Wieczorek, A., Drogosiewicz, M., Dembowska-Baginska, B. M., Bobeff, K. Ł., Mlynarski, W. M., Adamczewska-Wawrzynowicz, K., Wachowiak, J., Krawczyk, M. A., et al. (2024) · Cancers · doi:10.3390/cancers16050968 · Cited by 7
Fatahichegeni, M., Ansarian, M. A., Xiao, M., Gao, W., & Shi, R. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04384-1 · Cited by 6
Krijgsman, D., Schubert, S. A., Kraaier, L. J., Lu, Y., Avondt, K. V., Verdonschot, M. E. L., Leusen, J. H. W., van den Heuvel, M. C., de Kleine, R. H. J., de Meijer, V. E., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04164-3 · Cited by 6
Hall, C. P., Cronk, J. C., & Rubens, J. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci164420 · Cited by 4
Sentís, I., Melero, J. L., Cebria‐Xart, A., Grzelak, M., Soto, M., Michel, A., Rovira, Q., Rodríguez-Hernández, C. J., Caratù, G., Urpi, A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.530 · Cited by 6
Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000537969 · Cited by 6
“Similarly, in pediatric patients treated with ICIs, thyroid dysfunction is the most reported endocrinopathy, with hypothyroidism reported in 4 – 17% [18, 20 – 23, 25, 27 – 30, 33, 34, 36, 38, 39] and hyperthyroidism in 1 – 14% of patients [20 – 22, 30, 34, 38, 39].”
Zhong, X., Wen, X., Wang, X., Ye, J., Huang, L., Wang, J., Chi, J., & Zeng, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1576892 · Cited by 3
“However, it has been indicated that pediatric cancer patients with mismatch repair de fi ciencies and SMARC1B de fi ciency, which resulted in higher neoantigen burdens or increased immune cell in fi ltration, might show superior ef fi cacy with ICIs (34).”
Adoptive Cell Therapy for Pediatric Solid Tumors
Hont, A. B., & Bollard, C. M. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041636 · Cited by 3
Reis, P. C. A., Conrado, J. E. P., Noronha, M. M., da Silva, L. F. L., Saldanha, E. F., & Metts, J. L. (2025) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2025.100215 · Cited by 2
Du, Y., Qi, Z., Liang, X., Dai, J., Wei, X., Bai, X., Mao, L., Chi, Z., Cui, C., Lian, B., et al. (2024) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1401a26 · Cited by 2
“Compared with adult cancers, most pediatric cancers have lower mutational burdens and fewer infiltrating T cells, which may account for this lack of efficacy [15].”
BackgroundCharlab, R., Leong, R., Shord, S. S., & Reaman, G. H. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041656 · Cited by 2
Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1680081 · Cited by 1
Immune Checkpoint Inhibition in Pediatric Oncology Patients: A Single-Institution Experience
Wojciechowska, N., Orr, K., Albritton, K. H., Heym, K. M., Vallance, K., Murray, L., Aguilar, R., & Ray, A. (2024) · Hemato · doi:10.3390/hemato5010007 · Cited by 2
“Notably, therapies targeting the PD-1 pathway have been granted approval by the FDA for the treatment of eighteen different types of cancer in adults that affect the skin, lung, head and neck, genitourinary, gastrointestinal, and lymphoid systems [2].”
BackgroundMethodInfluentialVanssay, T. D., Riachy, N. E., Donzé, C., Appay, R., Scavarda, D., Testud, B., André, N., & Revon‐Rivière, G. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31399 · Cited by 1
Zhao, R., Chang, L., Zhang, C., He, R., & Wei, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1518987 · Cited by 1
Meligy, O. E., Elemam, N. M., Hassan, W. A., & Talaat, I. M. (2025) · Children · doi:10.3390/children12091249 · Cited by 2
“As a result, many immunotherapies that show efficacy in adult malignancies are frequently ineffective in children [86–88].”
Lin, A., Shen, J., Xie, Z., Cheng, Q., Zhang, J., & Luo, P. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70086 · Cited by 2
Pediatric thyroid side effects of immune checkpoint inhibitors
Morgante, C., Fierabracci, A., & Grossi, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.002 · Cited by 1
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · doi:10.1158/1078-0432.c.6678040 · Cited by 1
Self-citationClinical impact of molecular genetic testing in pediatric oncology
Dinikina, Y. V., Имянитов, Е. Н., Suspitsin, E. N., Zheludkova, O., Nikitina, I. L., & Belogurova, M. B. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-416
Tuzova, E. A., Евстратов, Д. А., Pshonkin, A. V., Korsantiya, M. N., Владимирович, Ф. И., Литвинов, Д. В., & Myakova, N. V. (2024) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2024-23-1-159-164
Basic Science, New Target Investigation, and Research in Childhood Cancer
Abdelhafeez, A. H., & Santana, V. M. (2025) · Springer eBooks · doi:10.1007/978-3-030-71113-9_52-1
Basic Science, New Target Investigation, and Research in Childhood Cancer
Abdelhafeez, A. H., & Santana, V. M. (2025) · Springer eBooks · doi:10.1007/978-3-030-71113-9_52-2
Basic Science, New Target Investigation, and Research in Childhood Cancer
Abdelhafeez, A. H., & Santana, V. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-76882-8_52
Raufaste-Cazavieille, V., Bianco, S., Herrmann, L., Clement, J. G., Texeraud, E., Langlois, S., Sontag, T., Tremblay-Dauphinais, P., Richard-St-Hilaire, A., Beauparlant, C. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.07.680325
Batra, S., Prabhakar, P., Mohapatra, D., George, N. G., Goel, N., Rishi, B., Misra, A., & Singh, A. (2025) · Onco · doi:10.3390/onco6010002
“These unique features contribute to the limited efficacy of single-agent checkpoint blockade in children, where response rates commonly remain below 10–15%, in stark contrast to adult outcomes [44].”
Manríquez, V. S., Cavada-Silva, S., Beccaria, K., Niborski, L. L., Leruste, A., Richer, W., Vandenbogaert, M., Han, Z., Sedlik, C., Denizeau, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.29.696858 · Cited by 1
Self-citationVäyrynen, V., Eloranta, K., Talka, M., Tuhkala, A., Lohi, J., Varjosalo, M. T., Kyrönlahti, A., Jalkanen, S., Hollmén, M., Pihlajoki, M., et al. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.05.006
Peters, C. W., Valenzuela-Cardenas, M., Kidd, C. K., Lechien, A., Dinh, A., Kawakami, M., Nguyen, J., Flores, A., Ma, S., Heady, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.731216
Kapitančukė, M., Petroška, D., Petrošiūtė, A., Lučiūnaitė, A., Grincevičienė, Š., Matulis, D., Ročka, S., Raugalas, R., Rinkevicius, D., Adomaitienė, I., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05678-1
Thyroid Hormone Parameters During Cancer Treatment In Children: Results Of The Thyro-Dynamics Study
van der Leij, S., Lebbink, C. A., Fiocco, M. F., Dierselhuis, M. P., Plasschaert, S. L. A., Stuart, A. A. V., van de Sande, J., Tissing, W. J. E., & van Santen, H. M. (2026) · Journal of Clinical Endocrinology and Metabolism · doi:10.52338/jocem.2026.6072
Wang, Y.-L., Lee, W., Chang, T., Hsiao, Y.-W., Wen, Y., Chen, S.-H., & Jaing, T. (2026) · Cancer Control · doi:10.1177/10732748261495568
Metadata
- Authors
- Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L.
- Affiliations
- Stanford Medicine (US)
- University of Toronto (CA)
- Université Paris Sciences et Lettres (FR)
- Institut Curie (FR)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 781-794
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280529326
- Cited by
- 53
- References
- 90
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 18 · 2023: 8 · 2022: 3
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- immune checkpoint inhibitors, childhood cancer, pediatric Hodgkin lymphoma, neoantigens, tumor immunogenicity, antitumor T-cell responses, immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Child, Hodgkin Disease, Humans, Immunologic Factors, Immunotherapy, Pediatrics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.